Seminars in Oncology
Volume 30, Issue 3 , Pages 349-360, June 2003

Follow-up strategies after curative resection of colorectal cancer

  • Jeffrey A. Meyerhardt

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, USA
    • Department of Medicine, Harvard Medical School, USA
    • *Address reprint requests to Jeffrey A. Meyerhardt, MD, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115 USA
    • 1J.A.M. is a trainee in the Program in Cancer Epidemiology, National Research Service Award T32 CA 090001-27.
  • ,
  • Robert J. Mayer

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, USA
    • Department of Medicine, Harvard Medical School, USA

Abstract 

Consensus is lacking as to the best strategy for following patients who have undergone definitive surgical medical treatment for colon cancer. The goal of any surveillance program should be detection of recurrent disease at a sufficiently early time to allow subsequent curative therapy. Although periodic clinical examinations, laboratory tests, radiographic imaging, and carcinoembryonic antigen (CEA) testing have been utilized as a form of surveillance, such aggressive and costly intervention has not been validated through clinical studies. Four of the five randomized trials comparing such an intensive surveillance strategy to less frequent testing have not demonstrated the intensive approach to lead to an improvement in overall survival. Furthermore, intensive testing is both costly and has been shown not to improve quality of life. Further research designing appropriate postoperative testing is needed to guide physicians and patients after the curative resection of a colorectal cancer.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(03)00095-2

Seminars in Oncology
Volume 30, Issue 3 , Pages 349-360, June 2003